Osteosarcoma is rare. It is the most common type of primary bone cancer, but primary bone cancers themselves are uncommon, and osteosarcoma easily falls under the U.S. threshold for a rare disease: any condition affecting fewer than 200,000 people. Roughly 800 to 900 new cases are diagnosed in the United States each year, making it a small fraction of all cancer diagnoses.
How Rare Compared to Other Cancers
To put it in perspective, breast cancer produces about 300,000 new U.S. cases annually. Lung cancer adds around 230,000. Osteosarcoma’s roughly 900 cases per year place it in a completely different category. Among primary bone cancers specifically, osteosarcoma accounts for about 35% of cases, followed by chondrosarcoma at 30% and Ewing sarcoma at 16%. So while osteosarcoma is the single most common bone cancer, that title comes from a very small pool.
Who Gets It and When
Osteosarcoma follows a distinctive two-peak pattern. The first and larger peak hits adolescents between ages 10 and 14, right when the pubertal growth spurt puts bones under the most rapid development. The second, smaller peak appears in adults over 65, where the cancer is more often linked to pre-existing bone conditions like Paget’s disease rather than arising on its own.
Between those two peaks, osteosarcoma is genuinely uncommon. A healthy 35-year-old developing it would be unusual. The adolescent peak is one reason the diagnosis can feel especially devastating: it disproportionately affects teenagers during an otherwise healthy stage of life.
Where It Typically Develops
Osteosarcoma overwhelmingly targets the long bones around the knee. The lower end of the thighbone (distal femur) and the upper shinbone (proximal tibia) are the two most common sites, which aligns with the growth-spurt connection since these areas grow rapidly during puberty. The upper arm bone (humerus) is the third most common location, accounting for 10% to 15% of all cases. Tumors can appear in other bones, including the pelvis and jaw, but those locations are less typical.
Why It’s Often Misdiagnosed at First
Rarity creates a real diagnostic problem. Most doctors, including orthopedic specialists, will go through an entire career seeing very few cases. The earliest symptom is usually pain or swelling near a joint, which in a teenager looks like a sports injury, growing pains, or tendinitis. Studies on bone sarcoma diagnoses found that the delay from first symptom to correct diagnosis ranges anywhere from 7 weeks to 28 months.
About 31% of osteosarcoma patients with limb tumors were initially diagnosed with tendinitis, and another 12% were told they had unexplained pain. Others were treated for trauma, arthritis, or sciatica before anyone ordered imaging that revealed a tumor. When the cancer occurs in the pelvis, the list of wrong diagnoses gets even longer: herniated discs, bursitis, stress fractures, hip arthritis, and even urinary tract infections have all been mistaken for what turned out to be osteosarcoma.
This isn’t necessarily negligence. Doctors reasonably start with common explanations for common symptoms. But the pattern highlights why persistent, worsening bone pain that doesn’t respond to rest or standard treatment deserves follow-up imaging, particularly in adolescents.
Genetic Conditions That Raise the Risk
Most osteosarcoma cases occur without any known genetic cause. However, several inherited syndromes carry a meaningfully elevated risk. The two most significant are Li-Fraumeni syndrome, caused by mutations in a key tumor-suppressing gene, and hereditary retinoblastoma, a childhood eye cancer caused by mutations in another tumor suppressor. People who survive hereditary retinoblastoma have a higher lifetime risk of developing osteosarcoma later.
A handful of rarer genetic conditions also increase risk. Rothmund-Thomson syndrome type 2, Werner syndrome, Bloom syndrome, and Diamond-Blackfan anemia all involve mutations that impair the body’s ability to repair or regulate DNA. These syndromes are themselves extremely rare, so they account for only a small slice of osteosarcoma cases overall. For most patients, no inherited cause is identified.
Survival Rates by Stage
Outcomes depend heavily on whether the cancer has spread at the time of diagnosis. For patients with localized disease (no detectable spread) who have the tumor completely removed surgically, five-year survival rates range from 64% to 79%. Those numbers reflect meaningful progress over earlier decades, when amputation was the standard approach and survival was lower.
About 17% of patients already have metastatic disease when first diagnosed, most commonly spread to the lungs. For this group, the picture is harder. A large international study of over 2,100 patients found a five-year survival rate of 45% for those who presented with metastases. Roughly 30% of metastatic patients survive five years from diagnosis, and about 20% remain continuously disease-free. These numbers underscore why early detection matters, even though the rarity of the disease makes early detection genuinely difficult.
What Rarity Means for Treatment
Being classified as a rare disease has practical consequences. Because the patient population is small, running large clinical trials is harder and takes longer. Drug companies have less financial incentive to develop treatments for a market of fewer than a thousand new patients per year. The FDA’s Orphan Drug Act tries to counteract this by offering incentives like tax credits and extended market exclusivity to companies that develop therapies for rare diseases. Osteosarcoma has received orphan drug designations for experimental treatments, though none of the newest candidates have reached FDA approval yet.
For patients, rarity also means that expertise is concentrated at specialized cancer centers. Community oncologists may see only a handful of bone cancer cases over many years. Treatment typically involves a combination of chemotherapy and surgery, and the surgical planning, especially around joints in growing adolescents, requires specialized orthopedic oncology skills that are most reliably found at major academic medical centers.